Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

19.97
-1.7100-7.89%
Post-market: 20.050.0800+0.40%19:23 EDT
Volume:4.61M
Turnover:93.44M
Market Cap:2.09B
PE:-2.80
High:21.67
Open:21.67
Low:19.72
Close:21.68
52wk High:72.05
52wk Low:10.42
Shares:104.79M
Float Shares:95.17M
Volume Ratio:0.71
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1300
EPS(LYR):-7.1300
ROE:-53.47%
ROA:-11.24%
PB:1.83
PE(LYR):-2.80

Loading ...

Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Feb 24

US court revives Regenxbio patent lawsuit over muscular dystrophy treatment

Reuters
·
Feb 21

Regenxbio Wins Appeal in Patent Dispute With Sarepta Therapeutics

MT Newswires Live
·
Feb 21

Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says

TIPRANKS
·
Feb 21

Earning Preview: Sarepta Therapeutics Q4 revenue is expected to decrease by 37.55%, and institutional views are bearish

Earnings Agent
·
Feb 18

Sarepta’s First siRNA Move in Huntington’s Disease Could Be A Game Changer For Sarepta Therapeutics (SRPT)

Simply Wall St.
·
Feb 16

Sarepta Therapeutics Inc. to Announce Fourth Quarter and Full-Year 2025 Financial Results

Reuters
·
Feb 11

Arrowhead   Pharmaceuticals  misses Q1 revenue estimates

Reuters
·
Feb 06

BUZZ-U.S. STOCKS ON THE MOVE-Bio-Techne, AbbVie, Johnson Controls

Reuters
·
Feb 04

BRIEF-Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease

Reuters
·
Feb 04

Sarepta Therapeutics Wins New Zealand Approval for First-in-Human SRP-1005 Trial

Reuters
·
Feb 04

Sarepta Therapeutics Announces Approval of Clinical Trial Application for Srp-1005, Its Investigational Treatment for Huntington’s Disease

THOMSON REUTERS
·
Feb 04

Sarepta Therapeutics Inc: First-in-Human Clinical Study of Srp-1005, Known as Insightt, Is Expected to Begin in Q2 of 2026

THOMSON REUTERS
·
Feb 04

Sarepta assumed with an Equal Weight at Barclays

TIPRANKS
·
Jan 28

Sarepta price target raised to $22 from $15 at Baird

TIPRANKS
·
Jan 27

Sarepta Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 27

H.C. Wainwright reiterates Sell on Sarepta after 3-year data

TIPRANKS
·
Jan 27

Sarepta Therapeutics Inc : Baird Raises Target Price to $22 From $15

THOMSON REUTERS
·
Jan 27

Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies

Reuters
·
Jan 26